Distinct molecular signatures in pediatric infratentorial glioblastomas defined by aCGH

Experimental and Molecular Pathology

Volumn 89, Issue 2, 2010, Pages 169-174

  Sharma, S ^a   Free, A ^a   Mei, Y ^a   Peiper, S C ^a,b   Wang, Z ^a,b   Cowell, J K ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

CGH; DNA copy number; Glioblastoma; Glioma; Molecular signature; Pediatric glioma

Indexed keywords

GLIAL FIBRILLARY ACIDIC PROTEIN;

ADOLESCENT; ARTICLE; ASTROCYTE; BRAIN STEM; CASE REPORT; CHILD; CHROMOSOME 16; CHROMOSOME 17P; CHROMOSOME 17Q; CHROMOSOME 1Q; CHROMOSOME 7; CHROMOSOME 8; CHROMOSOME LOSS; COMPARATIVE GENOMIC HYBRIDIZATION; COPY NUMBER VARIATION; FEMALE; GENETIC GAIN; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KARYOTYPE; MALE; POSTERIOR CRANIAL FOSSA TUMOR; PRESCHOOL CHILD; SCHOOL CHILD; SPINAL CORD; CEREBELLUM TUMOR; CHROMOSOME 17; CHROMOSOME ABERRATION; GENETICS; PATHOLOGY;

ADOLESCENT; CHILD; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 17; CHROMOSOMES, HUMAN, PAIR 7; CHROMOSOMES, HUMAN, PAIR 8; COMPARATIVE GENOMIC HYBRIDIZATION; DNA COPY NUMBER VARIATIONS; FEMALE; GLIOBLASTOMA; HUMANS; INFRATENTORIAL NEOPLASMS; MALE;

EID: 77956434284     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2010.06.009     Document Type: Article

References (46)

1. Brat D.J., Shehata B.M., Castellano-Sanchez A.A., et al. Congenital glioblastoma: a clinicopathologic and genetic analysis. Brain Pathol. 2007, 17:276-281.
2. Bredel M., Pollack I.F., Hamilton R.L., James C.D. Epidermal growth factor receptor expression and gene amplification in high-grade non-brainstem gliomas of childhood. Clin. Cancer Res. 1999, 5:1786-1792.
3. Cheng Y., Ng H.K., Zhang S.F., et al. Genetic alterations in pediatric high-grade astrocytomas. Hum. Pathol. 1999, 30:1284-1290.
4. Di Sapio A., Morra I., Pradotto L., Guido M., Schiffer D., Mauro A. Molecular genetic changes in a series of neuroepithelial tumors of childhood. J. Neurooncol. 2002, 59:117-122.
5. Donaldson S.S., Laningham F., Fisher P.G. Advances toward an understanding of brainstem gliomas. J. Clin. Oncol. 2006, 24:1266-1272.
6. Dufour C., Grill J., Lellouch-Tubiana A., et al. High-grade glioma in children under 5years of age: a chemotherapy only approach with the BBSFOP protocol. Eur. J. Cancer 2006, 42:2939-2945.
7. Ekstrand A.J., Sugawa N., James C.D., Collins V.P. Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails. Proc. Natl Acad. Sci. USA 1992, 89:4309-4313.
8. Fujisawa H., Reis R.M., Nakamura M., Colella S., Yonekawa Y., Kleihues P., Ohgaki H. Loss of heterozygosity on chromosome 10 is more extensive in primary (de novo) than in secondary glioblastomas. Lab Invest 2000, 80:65-72.
9. Galanis E., Buckner J., Kimmel D., et al. Gene amplification as a prognostic factor in primary and secondary high-grade malignant gliomas. Int. J. Oncol. 1998, 13:717-724.
10. Ganigi P.M., Santosh V., Anandh B., Chandramouli B.A., Sastry Kolluri V.R. Expression of p53, EGFR, pRb and bcl-2 proteins in pediatric glioblastoma multiforme: a study of 54 patients. Pediatr. Neurosurg. 2005, 41:292-299.
11. He J., Olson J.J., James C.D. Lack of p16INK4 or retinoblastoma protein (pRb), or amplification-associated overexpression of cdk4 is observed in distinct subsets of malignant glial tumors and cell lines. Cancer Res. 1995, 55:4833-4836.
12. Ichimura K., Bolin M.B., Goike H.M., Schmidt E.E., Moshref A., Collins V.P. Deregulation of the p14ARF/MDM2/p53 pathway is a prerequisite for human astrocytic gliomas with G1-S transition control gene abnormalities. Cancer Res. 2000, 60:417-424.
13. James C.D., Carlbom E., Dumanski J.P., et al. Clonal genomic alterations in glioma malignancy stages. Cancer Res. 1988, 48:5546-5551.
14. Jaros E., Perry R.H., Adam L., et al. Prognostic implications of p53 protein, epidermal growth factor receptor, and Ki-67 labeling in brain tumors. Br. J. Cancer 1992, 66:373-385.
15. Kirla R.M., Salminen E.K., Huhtala S., et al. Prognostic value of the expression of tumor suppressor genes p53, p21, p16 and pRb, and Ki-67 labelling in high grade astrocytomas treated with radiotherapy. J. Neurooncol. 2000, 46:71-80.
16. Kleihues P., Burger P.C., Aldape K.D., Brat D.J., Biernat W., Bigner D.D. Glioblastoma. WHO Classification of Tumours of the Central Nervous System 2007, 33-49. IARC Press, Lyon, France. D.N. Louis, H. Ohgaki, O.D. Wiestler, W.K. Cavenee (Eds.).
17. Korshunov A., Sycheva R., Gorelyshev S., Golanov A. Clinical utility of fluorescence in situ hybridization (FISH) in nonbrainstem glioblastomas of childhood. Mod. Pathol. 2005, 18:1258-1263.
18. Kraus J.A., Felsberg J., Tonn J.C., Reifenberger G., Pietsch T. Molecular genetic analysis of the TP53, PTEN, CDKN2A, EGFR, CDK4 and MDM2 tumour-associated genes in supratentorial primitive neuroectodermal tumours and glioblastomas of childhood. Neuropathol. Appl. Neurobiol. 2002, 28:325-333.
19. Leenstra S., Oskam N.T., Bijleveld E.H., Bosch D.A., Troost D., Hulsebos T.J. Genetic sub-types of human malignant astrocytoma correlate with survival. Int. J. Cancer 1998, 79:159-165.
20. Lo K.C., Bailey D., Burkhardt T., et al. Comprehensive analysis of loss of heterozygosity events in glioblastoma using the 100K SNP mapping arrays and comparison with copy number abnormalities defined by BAC array comparative genomic hybridization. Genes Chromosom. Cancer 2008, 47:221-237.
21. Lo K.C., Rossi M.R., Eberhart C.G., et al. Genome wide copy number abnormalities in pediatric medulloblastomas as assessed by array comparative genome hybridization. Brain Pathol. 2007, 17:282-296.
22. Lo K.C., Rossi M.R., LaDuca J., et al. Candidate glioblastoma development gene identification using concordance between copy number abnormalities and gene expression level changes. Genes Chromosom. Cancer 2007, 46:875-894.
23. Mellinghoff I.K., Wang M.Y., Vivanco I., Haas-Kogan D.A., Zhu S., Dia E.Q., et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J. Med. 2005, 353:2012-2024.
24. Nakamura M., Ishida E., Shimada K., Kishi M., Nakase H., Sakaki T., Konishi N. Frequent LOH on 22q12.3 and TIMP-3 inactivation occur in the progression to secondary glioblastomas. Lab. Invest. 2005, 85:165-175.
25. Nakamura M., Shimada K., Ishida E., et al. Molecular pathogenesis of pediatric astrocytic tumors. Neuro-Oncology 2007, 9:113-123.
26. Ohgaki H., Dessen P., Jourde B., et al. Genetic pathways to glioblastoma: a population-based study. Cancer Res. 2004, 64:6892-6899.
27. Ohgaki H., Kleihues P. Genetic pathways to primary and secondary glioblastoma. Am. J. Pathol. 2007, 170:1445-1453.
28. Pfister S., Remke M., Benner A., et al. Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci. J. Clin. Oncol. 2009, 27:1627-1636.
29. Pollack I.F. Current concepts: brain tumors in children. N Engl J. Med. 1994, 331:1500-1507.
30. Pollack I.F., Hamilton R.L., Finkelstein S.D., Campbell J.W., Martinez A.J., Sherwin R.N., Bozik M.E., Gollin S.M. The relationship between TP53 mutations and overexpression of p53 and prognosis in malignant gliomas of childhood. Cancer Res. 1997, 57:304-309.
31. Pollack I.F., Finkelstein S.D., Woods J., et al. Expression of p53 and prognosis in children with malignant gliomas. N Engl J. Med. 2002, 346:420-427.
32. Pollack I.F., Hamilton R.L., Burnham J., et al. The impact of proliferation index on outcome in childhood malignant gliomas: results in a multi-institutional cohort. Neurosurgery 2002, 50:1238-1245.
33. Pollack I.F., Finkelstein S.D., Burnham J., et al. The association between chromosome 1p and 19q loss and outcome in pediatric malignant gliomas: results from the CCG-945 cohort. Pediatr. Neurosurg. 2003, 39:114-121.
34. Pollack I.F., Boyett J.M., Yates A.J., et al. The influence of central review on outcome associations in childhood malignant gliomas: results from the CCG-945 experience. Neuro-Oncology 2003, 5:197-207.
35. Pollack I.F., Hamilton R.L., James C.D. Rarity of PTEN deletions and EGFR amplification in malignant gliomas of childhood: results from the Children's Cancer Group 945 cohort. J. Neurosurg. 2006, 105(suppl):418-424. Children's Oncology Group.
36. Raffel C., Frederick L., O'Fallon J.R., et al. Analysis of oncogene and tumor suppressor gene alterations in pediatric malignant astrocytomas reveals reduced survival for patients with PTEN mutations. Clin. Cancer Res. 1999, 5:4085-4090.
37. Ranuncolo S.M., Varela M., Morandi A., et al. Prognostic value of Mdm2, p53 and p16 in patients with astrocytomas. J. Neurooncol. 2004, 68:113-121.
38. Rasheed B.K., Stenzel T.T., McLendon R.E., et al. PTEN gene mutations are seen in high-grade but not low-grade gliomas. Cancer Res. 1997, 57:4187-4190.
39. Reifenberger G., Collins V.P. Pathology and molecular genetics of astrocytic gliomas. J. Mol. Med. 2004, 82:656-670.
40. Rossi M.R., Conroy J., McQuaid D., Nowak N.J., Rutka J.T., Cowell J.K. Array CGH analysis of pediatric medulloblastomas. Genes Chromosom. Cancer 2006, 45:290-303.
41. Sanders R.P., Kocak M., Burger P.C., Merchant T.E., Gajjar A., Broniscer A. High-grade astrocytoma in very young children. Pediatr. Blood Cancer 2007, 49:888-893.
42. Schmidt E.E., Ichimura K., Goike H.M., Moshref A., Liu L., Collins V.P. Mutational profile of the PTEN gene in primary human astrocytic tumors and cultivated xenografts. J. Neuropathol. Exp. Neurol. 1999, 58:1170-1183.
43. Sung T., Miller D.C., Hayes R.L., Alonso M., Yee H., Newcomb E.W. Preferential inactivation of the p53 tumor suppressor pathway and lack of EGFR amplification distinguish de novo high-grade pediatric astrocytomas from de novo adult astrocytomas. Brain Pathol. 2000, 10:249-259.
44. Suri V., Das P., Jain A., Sharma M.C., Borkar S.A., Suri A., Gupta D., Sarkar C. Pediatric glioblastomas: a histopathological and molecular genetic study. Neuro-Oncology 2009, 11:274-280.
45. Watanabe K., Tachibana O., Sato K., Yonekawa Y., Kleihues P., Ohgaki H. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol. 1996, 6:217-224.
46. Watanabe T., Nakamura M., Kros J.M., Burkhard C., Yonekawa Y., Kleihues P., Ohgaki H. Phenotype versus genotype correlation in oligodendrogliomas and low-grade diffuse astrocytomas. Acta Neuropathol. (Berl.) 2002, 103:267-275.